In line with these findings, pharmacological inhibition of mTOR/PI3K exerted anti‐cancer effects and decreased MYC levels in preclinical models of breast cancer, MM and AML [267, 268, 269], and suppressed the expression of MYC targets in CLL cells [95]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.